



**HTAi RICC Interest Group:
Regulatory Interactions & Conditional Coverage**

14 February 2018

Dear RICC IG members,

As we are getting close to our HTAi Annual Meeting, we take the liberty to reach out to you for updating you about the scope of the IG and a few upcoming activities.

Regulatory Interactions and Conditional Coverage (RICC) Interest Group (IG) focuses on the changing dynamics around evidence development that are leading to greater interaction with regulatory stakeholders as well as the increasing interest in mechanisms that involve conditionality of access relating specifically to evidentiary development.

The scope of this Interest Group includes:

- Adaptive pathways
- Early dialogue / scientific advice involving both regulators and HTA bodies
- HTA-Regulatory Interactions relating to evidence development
- Managed entry agreements (focussed on outcomes-based agreements)
 - Performance-linked Risk Sharing Agreements (PBRsAs)
 - Coverage with evidence development (CED)
 - Conditional treatment continuation (CTC)
- Post-marketing additional data collection

Our **newsletter** will be out in May before the Annual Meeting. It will present an excellent opportunity if you would like to publish any information, news or your point of view related to our scope. Please do not hesitate to reach out to our in case you would like to contribute

For your information, the previous Newsletter can be found on the HTAi website at:
https://www.htai.org/fileadmin/HTAi_Files/ISG/RegulatoryInteractions/RICCNNewsletters/RICC_Newsletter_May_2017.pdf

Three **RICC supported abstracts** are now accepted for the Annual Meeting. Please join us and the rest of RICC IG members in these events:

- **Workshop:** A Primer in Regulatory Interactions and Conditional Coverage
- **Panel:** Conditional Coverage & Value Based Healthcare: From Theory to Practice in Aligning Dialogue Around the Patient
- **Oral presentation:** HTA, From Reacting to Innovation to Proactively Involved in Technology Development. Lessons Learnt and Ways Forward

This is also the best timing if you would like to suggest any **collaboration teams** to work on the topic of your interest within the scope of RICC IG. We can make an announcement in our upcoming Newsletter and then help you with finding collaborators during the HTAi Annual Meeting.

Kind regards,

Dr Massoud Toussi, IQVIA, (Massoud.toussi@iqvia.com), RICC IG Chair

Michelle, François and Richard, Please add your emails

Dr Franz Pichler, Eli Lilly, (fpichler@lilly.com), RICC IG ex-Chair